Award Number: W81XWH-13-1-0198

TITLE: The Role of Akt Isoforms in Colorectal Cancer

PRINCIPAL INVESTIGATOR: Jatin Roper

CONTRACTING ORGANIZATION: Tufts Medical Center Inc.
Boston, MA 02111

REPORT DATE: September 2015

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
**Abstract**

Akt activation is found in many cancers, including CRC, and is a marker for CRC initiation and progression. However, since Akt has a central role in cell signaling, targeting the three Akt isoforms concurrently may give rise to unacceptable toxicity. Therefore, selective inhibition of one or more Akt isoforms or their target phosphoproteins may be a more effective treatment strategy for CRC. Though a phosphoproteomics screen, we identified 20 Akt isoform-specific phosphorylation targets as likely to be involved in tumor growth and metastasis. We hypothesized that Akt isoforms and their downstream effectors play essential roles in CRC induction, growth and metastasis. We have found that knockout of Akt1 or Akt2 substantially reduces colorectal tumorigenesis in our genetically engineered mouse model. We also successfully ablated novel downstream targets of Akt in our novel murine colorectal cancer cell lines: IWS1, MTSS1 or MIM, FRMD6, SEMA4B, MYH9, and Liprin-β1. We found that each phosphorylation target promotes tumorigenesis in vitro. MTSS1 had the greatest effect on in vitro tumorigenesis.

**Subject Terms**

colorectal cancer, Akt
Introduction

Colorectal cancer (CRC) is the third leading cause of cancer-related mortality worldwide, with approximately 600,000 deaths each year. The five-year prognosis for patients with newly diagnosed metastatic CRC is less than 20%. Understanding the key cellular signaling pathways that promote formation of CRC metastases is critical to the development of novel treatment strategies.

Akt activation is a common theme in many cancers, including CRC, and is a marker for CRC initiation and progression. As a result, Akt has been identified as an important molecular target for cancer therapy. However, since Akt has a central role in cell signaling, targeting the three Akt isoforms (Akt1, Akt2, and Akt3) concurrently may give rise to unacceptable toxicity. Therefore, selective inhibition of one or more Akt isoforms or their target phosphorylated proteins may be a more effective treatment strategy for CRC.

Using triple Akt knockout cells from mice which were engineered to express one Akt isoform at a time but were otherwise identical, the Tsichlis laboratory collaborated with Cell Signaling Technologies, Inc., to identify 20 Akt isoform-specific phosphorylation targets using an unbiased phosphoproteomics screen which are likely to be involved in tumor invasion and metastasis. We selected six of these targets which are strongly expressed in colonic tumors relative to normal colonic mucosa: IWS1, the metastasis suppressor MTSS1L or MIM, the FERM domain protein and Merlin interactor FRMD6, the type I transmembrane protein SEMA4B, the non-muscle myosin heavy chain NMHCIIA/MYH9 which interacts with the metastasis-associated protein S1004A and LIPRIN-β1, which interacts with the metastasis-promoting protein S1004A.

Body

Aim 1: To determine the role of Akt1 and Akt2 in the induction, invasiveness and metastatic potential of colorectal tumors.

Sub-aim 1a: Evaluate the effect of colon-specific Akt1 and Akt2 ablation on tumorigenesis.

We have extensive experience with a novel genetically engineered mouse (GEM) model of CRC in which adenovirus expressing cre recombinase (adeno-cre) is delivered to the distal colon of mice carrying a floxed Apc exon 14 allele (Apc mice with deletion of the Apc gene) and an additional lox-stop-lox (LSL) Kras G12D allele (Apc-Kras mice). These mice are a more accurate model for sporadic and metastatic CRC: 1) animals develop one or two tumors in the distal colon; 2) the tumors derive from somatic modification of genes known to be involved in CRC; 3) the somatic mutations involve the colonic epithelium; 4) tumors recapitulate the entire adenoma-carcinoma-metastasis sequence, with liver metastases forming in approximately 50% of mice six months following tumor induction; 5) tumor size can be monitored in vivo using optical colonoscopy; and 6) sequential tumor biopsy can be performed for genetic and biochemical analysis. We crossed Akt1fl/fl mice and Akt2fl/fl mice with Apcfl/flKrasG12D mice to derive Apcfl/flKrasG12DAkt1fl/fl, Apcfl/flKrasG12DAkt2fl/fl, Apcfl/flKrasG12DAkt WT mice. We then performed surgical laparatomies on 20 mice from each group, isolated the distal colon, and delivered adeno-cre by rectal enema, as previously described. Tumor formation was assessed by optical colonoscopy four weeks after tumor induction using a custom endoscopy system. We found that ablation either Akt1 or Akt2 resulted in decreased tumor formation rate and tumor size index (a proxy for tumor size) (Figure 1).
6 months after tumor induction, we performed MRI scans of mice with colonoscopic tumors following administration of gadolinium. Liver metastases were visible on MRI (Figure 2). The liver metastasis rate was significantly lower in Akt2 and Akt3 fl/fl groups compared to the control group. All MRI imaging was performed at the Small Animal Imaging/Tumor Biology Facility of Tufts University.

**Figure 1:** Distal colonic tumors were induced in \( \text{Apc}^{\text{fl/fl}} \text{Kras}^{G12D} \text{Akt WT, Apc}^{\text{fl/fl}} \text{Kras}^{G12D} \text{Akt1 fl/fl, and Apc}^{\text{fl/fl}} \text{Kras}^{G12D} \text{Akt2 fl/fl} \) mice via surgical administration of adenocre. 4 weeks later, we assessed tumor initiation rate (A) and tumor size (B) by optical colonoscopy. Representative colonoscopy images are shown in (C). * \( P<0.01 \).

**Figure 2:** Liver metastasis formation was assessed in \( \text{Apc}^{\text{fl/fl}} \text{Kras}^{G12D} \text{Akt WT, Apc}^{\text{fl/fl}} \text{Kras}^{G12D} \text{Akt1 fl/fl, and Apc}^{\text{fl/fl}} \text{Kras}^{G12D} \text{Akt2 fl/fl} \) mice that had colonic tumors present on colonoscopy. We performed MRI scans post gadolinium administration. * \( P<0.01 \). (Square; tumor metastasis)
Following MRI scanning, mice were sacrificed and tumor (primary colon and liver) tissue was divided for subsequent histology and biochemical analysis. These studies are ongoing.

**Aim 2: To determine the role of Akt isoform-dependent phosphorylation events in CRC growth and metastasis.**

**Sub-Aim 2a:** To evaluate the role of Akt isoform-dependent phosphorylation targets in cellular growth and invasion.

We transduced the C57BL/6 mouse-derived colorectal tumor cell line F62 with lentiviral short hairpin (sh) RNA constructs or shControl to knock down the endogenous proteins IWS1, MTSS1 or MIM, FRMD6, SEMA4B, MYH9, and Liprin-β1. We then replaced with the exogenous wild type or phosphorylation site mutant proteins that were created using insertional mutagenesis. Immunoprecipitation studies were performed for each phosphorylation target to demonstrate that the wild-type, but not mutant, protein is phosphorylated by Akt. A representative immunoprecipitation study for MTSS1 is shown in Figure 3.

Next, we assess cellular proliferation in wild-type and mutant IWS1, MTSS1, FRMD6, SEMA4B, MYH9, and Liprin-β1. 1000 cells were seeded in 96 well plates, grown for 72 hours, then assessed cell viability by the Cell Titer Glo chemiluminescent assay. We then determined cell migration by seeding cells to confluence in 6 well plates, creating a wound with a pipette tip, then assessing percent wound closure after 24 hours (Figure 4).
Sub-Aim 2b: To assess the role of Akt target phosphorylated proteins in tumor growth in vivo.

Results:
We developed an orthotopic transplantation model of colorectal cancer in which murine B6 colorectal cancer cells are transplanted via colonoscopy injection needle into the lamina propria of recipient mice (Figure 5 below).

Focusing on MTSS1, we performed orthotopic transplantation studies with WT, shMTSS1, and mutant MTSS1 F62 colorectal cancer cells. We found that mutant MTSS1 cells formed significantly smaller tumors than WT cells.

Next, we sought to identify mechanisms by which Akt-specific phosphorylation of MTSS1 promotes colorectal tumorigenesis.

Results – Akt-specific phosphorylation of MTSS1 promotes Hedgehog signaling in colorectal cancer

Mtss1 is phosphorylated by Akt at Ser594. We ablated Mtss1 expression in HT-29 CRC cells with a short hairpin (sh) RNA targeting the 5' UTR and rescued expression with FLAG-tagged wild-type Mtss1 or mutant Mtss1 with the Ser594 phosphorylation residue replaced with alanine (S594A) via insertional mutagenesis (“A Mutant”). Immunoprecipitation studies in wild-type and mutant Mtss1 cells demonstrated that Mtss1 is phosphorylated by Akt at Ser594 (Figure 5).

Figure 6. Mtss1 is phosphorylated by Akt at Ser594.
Mtss1 was ablated in DLD-1 colorectal cancer cells with short hairpin (sh) RNA to the 5’ UTR, then rescued with wild-type (WT) FLAG-tagged Mtss1 or mutant (mut) FLAG-tagged Mtss1 expressing Ala594 instead of Ser594. WT or mut Mtss1 cells treated with DMSO or a pan-AKT inhibitor (MK-2206, 5µM) were immunoprecipitated with anti-FLAG antibody bound to sepharose beads, then probed with a universal phospho-Akt substrate antibody (RxxS/T*).

Akt-dependent phosphorylation of Mtss1 promotes proliferation of colorectal cancer cells through Hedgehog signaling. The Hedgehog ligand Indian hedgehog (Ihh) is expressed in the adult intestine and is required for Wnt-driven intestinal tumorigenesis. Mtss1 is a Hedgehog target gene that is also essential for transcription of Hedgehog target genes by interacting with Hedgehog pathway components and by binding to the Gli promoter response element. We therefore examined the role of Akt-specific phosphorylation of Mtss1 in Hedgehog signaling, and found that phosphorylated Mtss1 promotes transcription of the Hedgehog target genes GLI1, BCL2, BMP7, and WNT2B in HT-29 cells (Figure 7A). We then examined the role of phosphorylated Mtss1 in Hedgehog-dependent cell proliferation. We found that phosphorylation of Mtss1 by Akt promotes cellular proliferation of HT-29 cells (Figure 7B) and mouse embryonic fibroblasts with activation of the Hedgehog pathway (i.e, Ptc1-/- MEFs), but not Ptc1 WT MEFs or Ptc1-/- MEFs treated with a Hedgehog inhibitor (cyclopamine) (Figure 7C). These findings demonstrate that Hedgehog signaling is necessary and sufficient for the effect of Akt-specific phosphorylation of Mtss1 on colorectal cancer cell proliferation.
Mtss1 interacts with the Gli1/Suppressor of Fused complex via phosphorylation of Ser594 by Akt.

Mtss1 potentiates Gli1-dependent Hedgehog signaling by binding to the Gli1/Suppressor of Fused (Sufu) complex, but the mechanism of this interaction has not been elucidated.[15] We used insertional mutagenesis to generate a phosphomimetic Ser594Asp or “D-mut” FLAG-Mtss1 clone. We immunoprecipitated FLAG-Mtss1 from WT, A-Mut, and D-Mut HT-29 cells, then blotted for endogenous Gli1 and Sufu. We found that loss of Akt-specific phosphorylation at Ser594 (A-Mut) resulted in loss of Mtss1-Gli1 and Mtss1-Sufu binding; this phenotype was rescued by the D mutant Mtss1 line (Figure 7). These findings provide mechanistic support for our hypothesis that Akt-specific phosphorylation of Mtss1 is essential for Hedgehog signaling.

Sub-Aim 2c: To determine the association between Akt isoform-dependent phospho-proteins and human CRC tumor stage.

Results:

Focusing on MTSS1, we developed an AKT-specific phospho-MTSS1 antibody, then performed immunohistochemistry for P-MTSS1 on human CRC tumor microarrays. We are currently analyzing these data with our pathologist to score each sample and correlate tumor stage with MTSS1 phosphorylation status.

Key research accomplishments

1. Akt1 and Akt2 promote colorectal tumorigenesis.
2. Akt1 and Akt2 promote liver metastasis of colorectal primary tumors.
3. We successfully created lentiviral constructs expressing wild-type IWS1, MTSS1, FRMD6, SEMA4B, MYH9, and Liprin-β1 or mutant protein that is not phosphorylated by Akt. Endogenous protein was knocked down by shRNA.
4. For all selected phosphorylation targets, Akt-specific phosphorylation promotes cellular proliferation and migration in vitro.
5. Akt-specific phosphorylation of MTSS1 promotes in vivo colorectal tumorigenesis. We believe this effect is dependent on Hedgehog signaling.
6. We developed a phospho-MTSS1 antibody, which we are currently using to correlate CRC tumor grade with MTSS1 phosphorylation status.

Reportable outcomes

I have received a V Scholar Award from the V Foundation based on work supported by the DOD Career Development Award.

I have received a K08 career development award from the National Cancer Institute based on work supported by the DOD Career Development Award.

I published a last author review paper and a co-first author paper in Nature. These publications are based on techniques that I developed while supported by the DOD Award:

   PMID: 26295972
   PMID: 26935695

Conclusions

Akt isoforms are independently important for colorectal carcinogenesis. The six selected novel Akt phosphorylation targets play an important role colorectal cell growth and migration in vitro. MTSS1, in particular, promotes in vivo tumorigenesis via regulation of Hedgehog signaling.

References

Appendices

None